1.Analysis of unmet supportive care needs in patients with thyroid cancer during 13I treatment
Suyun FAN ; Li CHAI ; Yanyan JIA ; Zhongwei LYU ; Qingqing HUANG ; Yanbo WANG
Chinese Journal of Nuclear Medicine and Molecular Imaging 2018;38(6):422-424
Objective To investigate the unmet needs of thyroid cancer patients undergoing 131Itreatment and their relationship with psychological distress and quality of life.Methods From October 2014 to March 2016,a total of 338 patients (106 males,232 females,average age (35.50±9.98) years) with thyroid cancer who were receiving 131I treatment were enrolled.The 34 items of Supportive Care Needs Survey Short Form (SNCS-SF34) were used to investigate the unmet care needs of patients.Patients' perceptions of distress and main causes of distress were measured by Distress Thermometers (DT) and issue list.The 12-item Short-Form Health Survey (SF-12) was used to measure patients' quality of life.Pearson correlation analysis was used to analyze the data.Results The degrees of patients' unmet care needs from high to low were as following:health information needs (65.38%,221/338),psychological needs (47.93%,162/338),patients' care and support needs (44.08%,149/338),physical and daily needs (36.09%,122/338) and sexual needs (34.32%,116/338).There were 47.93%(162/388) patients with DT score > 4.The top three causes of patients' distress were fears,fatigue and memory deterioration.Degree of unmet needs for patients had positive correlation with the degree of psychological distress (r values:0.232-0.462,all P<0.01).The unmet physiological and daily needs and psychological needs of patients had negative correlations with several dimensions of quality of life (r values:from-0.367 to-0.202,all P< 0.05).Conclusions The unmet care needs of patients with thyroid cancer have correlations with their psychological distress and quality of life.Evaluation of the unmet care needs of patients with thyroid cancer could be beneficial for providing the targeted care.
2.Effect of tail vein transplantation of human amniotic mesenchymal stem cells with different transforming growth factor-β expressions on sciatic nerve function in xenografted mice
Mubin CHEN ; Qingqing LI ; Huihui CHAI ; Kuntai XIAO ; Xiaoguang HUANG ; Yuting XU ; Shan XUE ; Haitao SUN ; Yanwu GUO
Chinese Journal of Neuromedicine 2020;19(1):9-16
Objective To investigate the effect of tail vein transplantation of human amniotic mesenchymal stem cells (hAMSCs) with different transforming growth factor (TGF)-β expressions on recovery of sciatic nerve function in peripheral nerve xenotransplantation mice.Methods The hAMSCs were isolated from amnion membranes by healthy mother donors and identified by fluorescence activated cell sorter.The up-regulated and down-regulated TGF-β lentiviral plasmids were constructed and transfected into the purified hAMSCs;hAMSCs with stable up-regulated or down-regulated TGF-β expression were constructed.The sciatic nerves of C57BL/6 mice were isolated and cut out,and sciatic nerves of SD rats were isolated and transplanted into the sciatic nerve defected C57BL/6 mice to construct peripheral nerve xeno-transplanted mice models;these mice models were divided into 4 groups (n=10)according to random number table:control group,hAMSCs treatment group,high-expressed TGF-βhAMSCs treatment group,and low-expressed TGF-β hAMSCs treatment group;one d before modeling,phosphate buffer saline (PBS) or hAMSCs re-suspension were drawn with a syringe and slowly pushed into the tail veins of mice for transplantation treatment;14 d after treatment,DigGait analysis system was used to evaluate the recovery of sciatic nerve function in each group of mice.Result Fourteen d after treatment,the sciatic nerve function index (SFI) of the high-expressed TGF-β hAMSCs treatment group (-25.820±0.286) was significantly higher than that of the low-expressed TGF-β hAMSCs treatment group (-33.413±0.920) and hAMSCs treatment group (-30.755±0.421,P<0.05).Conclusion The tail vein transplantation of hAMSCs with TGF-β high expression can effectively improve the sciatic nerve function in peripheral nerve xenotransplantation mice,which may be a new breakthrough in the treatment of peripheral nerve defects.
3.Comparison of evaluation system for clinical value of antineoplastic agents at home and abroad
Yitian LANG ; Qingqing CHAI ; Yahui LIAO ; Xiaoyan LIU ; Yuanjia HU
China Pharmacy 2022;33(11):1287-1294
OBJECTI VE To introduce the evaluation system for clinical value of antineoplastic agents at home and abroad ,and to provide reference for continuous improvement of clinical value-oriented antineoplastic agents development and research guideline in China. METHODS The suggestions were put forward to improve the evaluation system for clinical value of antineoplastic agents in China by consulting the relevant data of evaluation system for clinical value of antineoplastic agents at home and abroad and domestic antineoplastic agents R&D and management policies ,sort outing and analyzing comparatively their dimensions , perspectives,target audiences ,application scope ,advantages and disadvantages. RESULTS & CONCLUSIONS Seven foreign value evaluation systems (value assessment framework of American Society of Clinical Oncology ,clinical benefit scale of European Society of Clinical Oncology ,value evaluation framework of American Institute of Clinical and Economic Evaluation , etc.)had their own characteristics and unique advantages under different settings ;several value evaluation systems differed in the criteria for defining value ,depending on the perspective and population they focus on. The value dimensions were constantly changing dynamically in response to scientific values and social needs ,including not only safety ,efficacy and cost-effectiveness , but also innovation ,fairness,quality of life attributes. Some evaluation systems adopted value assessment tools that followed the trend of the information age in the presentation form and assessment mode ,which promoted shared decision-making between doctors and patients. Combining the characteristics of foreign value evaluation system and the current situation of development and application of antineoplastic agents in China ,we can have a deeper understanding of drug efficacy ,safety,quality of life ,research and development cost and pricing in the future. Antineoplastic 2021-10-28) agents will have a more reasonable position to solve the unmet needs of patients from the perspectives of drug research and development, clinical application , drug accessibility and fairness.